[Neoton (exogenic phosphocreatinine) in combined therapy of chronic cardiac failure].
To evaluate clinicohemodynamic effect of neoton (exogenic phosphocreatine) given in an intravenous course, the drug was added to standard scheme in 53 patients with chronic cardiac failure (6.0 g/day i.v. drip for 5 days or 3.0 g/day for 10 days). 20 control patients received standard therapy alone. A course neoton produced an increase in the ejection fraction, a reduction in end-diastolic and end-systolic left ventricular volumes. It is recommended to include neoton in the scheme of chronic cardiac failure treatment in the dose 3.0 g/day for 10 days.
Nedoshivin
A O
AO
NII of Cardiology, Saint-Petersburg.
Perepech
N B
NB
D002316:Cardiotonic Agents / Q000627:therapeutic use; D002908:Chronic Disease; D004232:Diuretics / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010725:Phosphocreatine / Q000008:administration & dosage*; D016896:Treatment Outcome
D002316:Cardiotonic Agents; D004232:Diuretics; D010725:Phosphocreatine